inclusion criteria: * age greater than or equal to 18 years of age * ability to understand and sign informed consent * biopsy-proven diagnosis of previous cancer (solid or hematologic disease) * participants must be diagnosed with active malignancy, defined as the presence of metastatic disease; or patient undergoing curative treatment during cancer treatment, regardless of the therapeutic modality. * confirmed diagnosis of covid-19 by the presence of a positive pcr test or positive serological test and / or diagnosis presumed by the presence of flu-like symptoms associated to suggestive findings on ct scan. * ecog performance status 0 to 2 * patients must have an assessment of adequate organ function within 28 days prior to enrollment, evidenced by: * hemoglobin ≥ 9.0 g / dl * leukometry\> 2,000 / mm3 * absolute neutrophil count ≥ 1,500 / mm3 * platelet count ≥ 100,000 / mm3 * creatinine clearance ≥ 30 ml / min. creatinine clearance (crcl) should be calculated according to the cockcroft-gault formula. * total bilirubin \<3 x the upper limit of normal (uln), except for patients with known gilbert's syndrome. * aspartate aminotransaminase (ast) \<3.0 x lsn. * alanine aminotransaminase (alt) \<3.0 x uln.

inclusion criteria: * age greater than or equal to 18 years of age * ability to understand and sign informed consent * biopsy-proven diagnosis of previous cancer (solid or hematologic disease) * participants must be diagnosed with active malignancy, defined as the presence of metastatic disease; or patient undergoing curative treatment during cancer treatment, regardless of the therapeutic modality. * confirmed diagnosis of covid-19 by the presence of a positive pcr test or positive serological test and / or diagnosis presumed by the presence of flu-like symptoms associated to suggestive findings on ct scan. * ecog performance status 0 to 2 * patients must have an assessment of adequate organ function within 28 days prior to enrollment, evidenced by: * hemoglobin ≥ 9.0 g / dl * leukometry\> 2,000 / mm3 * absolute neutrophil count ≥ 1,500 / mm3 * platelet count ≥ 100,000 / mm3 * creatinine clearance ≥ 30 ml / min. creatinine clearance (crcl) should be calculated according to the cockcroft-gault formula. * total bilirubin \<3 x the upper limit of normal (uln), except for patients with known gilbert's syndrome. * aspartate aminotransaminase (ast) \<3.0 x lsn. * alanine aminotransaminase (alt) \<3.0 x uln.

inclusion criteria: - age greater than or equal to 18 years of age - ability to understand and sign informed consent - biopsy-proven diagnosis of previous cancer (solid or hematologic disease) - participants must be diagnosed with active malignancy, defined as the presence of metastatic disease; or patient undergoing curative treatment during cancer treatment, regardless of the therapeutic modality. - confirmed diagnosis of covid-19 by the presence of a positive pcr test or positive serological test and / or diagnosis presumed by the presence of flu-like symptoms associated to suggestive findings on ct scan. - ecog performance status 0 to 2 - patients must have an assessment of adequate organ function within 28 days prior to enrollment, evidenced by: - hemoglobin ≥ 9.0 g / dl - leukometry> 2,000 / mm3 - absolute neutrophil count ≥ 1,500 / mm3 - platelet count ≥ 100,000 / mm3 - creatinine clearance ≥ 30 ml / min. creatinine clearance (crcl) should be calculated according to the cockcroft-gault formula. - total bilirubin <3 x the upper limit of normal (uln), except for patients with known gilbert's syndrome. - aspartate aminotransaminase (ast) <3.0 x lsn. - alanine aminotransaminase (alt) <3.0 x uln.

inclusion criteria: - age greater than or equal to 18 years of age - ability to understand and sign informed consent - biopsy-proven diagnosis of previous cancer (solid or hematologic disease) - participants must be diagnosed with active malignancy, defined as the presence of metastatic disease; or patient undergoing curative treatment during cancer treatment, regardless of the therapeutic modality. - confirmed diagnosis of covid-19 by the presence of a positive pcr test or positive serological test and / or diagnosis presumed by the presence of flu-like symptoms associated to suggestive findings on ct scan. - ecog performance status 0 to 2 - patients must have an assessment of adequate organ function within 28 days prior to enrollment, evidenced by: - hemoglobin ≥ 9.0 g / dl - leukometry> 2,000 / mm3 - absolute neutrophil count ≥ 1,500 / mm3 - platelet count ≥ 100,000 / mm3 - creatinine clearance ≥ 30 ml / min. creatinine clearance (crcl) should be calculated according to the cockcroft-gault formula. - total bilirubin <3 x the upper limit of normal (uln), except for patients with known gilbert's syndrome. - aspartate aminotransaminase (ast) <3.0 x lsn. - alanine aminotransaminase (alt) <3.0 x uln.